ライフサイエンスコーパス: adenopathy

1 ce of supraclavicular or contralateral hilar adenopathy.

2 dard of care for the sampling of mediastinal adenopathy.

3 nciclovir, can control symptoms and decrease adenopathy.

4 tumour in patients who present with axillary adenopathy.

5 rall survival (OS) among patients with bulky adenopathy.

6 inct), calcification, growth, and associated adenopathy.

7 or suspected lung carcinoma and mediastinal adenopathy.

8 ng patients with lung cancer and mediastinal adenopathy.

9 for pretracheal, hilar, and high pretracheal adenopathy.

10 t cancer in patients with malignant axillary adenopathy.

11 examination were known did not have palpable adenopathy.

12 There was no palpable axillary adenopathy.

13 ly liver masses followed by lung nodules and adenopathy.

14 agnosis of patients with unilateral axillary adenopathy.

15 pulmonary abnormalities (150 of 1558, 9.6%), adenopathy (103 of 1558, 6.6%), renal lesions (101 of 15

16 61%), and presented with massive mediastinal adenopathy (70%).

17 autoimmune disease but has little effect on adenopathy, administration of anti-CD40L to MRL-lpr mice

18 lso associated with the severity of inguinal adenopathy among men with hydrocele.

19 Additional findings included adenopathy and adrenal and pulmonary metastases.

20 ted in the 1st year of life with symptoms of adenopathy and hepatosplenomegaly.

21 Chest radiograph revealed hilar adenopathy and left pleural effusion; computed tomograph

22 ember 1997, 38 women with malignant axillary adenopathy and negative mammographic and physical examin

23 However, mediastinal adenopathy and pleural effusions were significantly more

24 apoptosis manifests as chronic, nonmalignant adenopathy and splenomegaly; the expansion of an unusual

25 cyte apoptosis permits chronic, nonmalignant adenopathy and splenomegaly; the survival of normally un

26 In the past, hilar adenopathy and/or mediastinal mass have been considered

27 bin <10 g/L, platelets <100 x 10(9)/L, bulky adenopathy and/or organomegaly, symptomatic hyperviscosi

28 s, syndromes 4 ("phobia-apraxia"), 5 ("fever-adenopathy"), and 6 ("weakness-incontinence") involved w

29 taging: size, necrosis, associated findings, adenopathies, and perfusion and diffusion parameters.

30 primary breast cancer, no palpable axillary adenopathy, and 1 or 2 sentinel lymph nodes containing m

31 invasive breast cancer, no palpable axillary adenopathy, and 1 or 2 sentinel lymph nodes containing m

32 al T1-T2 invasive breast cancer, no palpable adenopathy, and 1 to 2 SLNs containing metastases identi

33 m right upper lobe mass, without mediastinal adenopathy, and a 6-cm cystic mass in the spleen.

34 op severe hypergammaglobulinemia, lymph node adenopathy, and autoimmune disease.

35 s with fludarabine-refractory disease, bulky adenopathy, and del(17p) CLL.

36 (AEs) reported were injection site rash and adenopathy, and four participants experienced a grade 1

37 pleural effusions, mediastinal and cervical adenopathy, and no gastrointestinal lesion.

38 uated for parenchymal opacities, cavitation, adenopathy, and pleural effusions.

39 infected patients with mediastinal and hilar adenopathy at Bellevue Hospital Center.

40 The adenopathy at US was hyper- and/or isoechoic relative to

41 woman with mild Covid-19 developed cervical adenopathy, being diagnosed of Epstein-Barr virus infect

42 coronavirus disease 2019 developed cervical adenopathy, being diagnosed of Epstein-Barr virus infect

43 as a key technique for sampling mediastinal adenopathy but variable yields are reported.

44 led well-resolved spikes in fever, rash, and adenopathy diagnoses, with the maximum incidence occurri

45 C) and 11 (92%) of 12 patients with palpable adenopathy experiencing at least a 50% reduction in the

46 blic is the way forward in the management of adenopathy following COVID-19 vaccination.

47 and characteristics of mammographic axillary adenopathy following COVID-19 vaccination.

48 compared to 12% of the wild type, developed adenopathy, hepatosplenomegaly, and circulating lymphobl

49 ns; these include seromas or late infection; adenopathies in the internal mammary chain; granulomas i

50 A pattern of spiculated axillary adenopathy in a patient with breast cancer appears to be

51 effective in the diagnosis of intrathoracic adenopathy in HIV-infected patients, and is particularly

52 sed a 5.2-cm intraparotid mass and extensive adenopathy in the ipsilateral cervical and submental cha

53 On examination, she had adenopathy in the left axillary and supraclavicular regi

54 idered of the highest priority when managing adenopathy in the setting of COVID-19 vaccination.

55 ted extraintestinal findings (eg, mesenteric adenopathy in two patients, perianal and enterocolic fis

56 Vaccination-associated adenopathy is a frequent imaging finding after administr

57 ial for COVID-19 vaccine-related ipsilateral adenopathy is necessary to avoid unnecessary biopsy and

58 tomography of the chest showing mediastinal adenopathy led to a presumptive diagnosis of inhalationa

59 galy, retroperitoneal adenopathy, periportal adenopathy, mesenteric adenopathy, thickening of the ome

60 brospinal fluid (CSF) pleocytosis, and hilar adenopathy more frequently than NMOSD (p < 0.05); CSF hy

61 nonseminomatous germ cell tumor (NSGCT) with adenopathy more than 2 cm, multiple masses, elevated ser

62 masses, gastric ulcer, small hypermetabolic adenopathies, multiple focal bone marrow uptake and inte

63 with periappendiceal fat stranding (n = 14), adenopathy (n = 6), appendolith(s) (n = 4), or fluid (n

64 ar consolidation (n = 3), and/or mediastinal adenopathy (n = 8).

65 Patients were stratified by adenopathy (no vs yes [coeliac absent] vs yes [coeliac p

66 Seventeen patients with metastatic cervical adenopathy of unknown primary origin were referred for F

67 are non-nodular enhancement, size>25mm, and adenopathies on MRI, and p53 expression <15% on histopat

68 bles MRI size>25mm, non-nodular enhancement, adenopathies on MRI, and p53 expression <15% were indepe

69 -caseating granulomata or 2) bilateral hilar adenopathy on chest imaging.

70 2 WG registries to obtain evidence of hilar adenopathy or mediastinal masses.

71 latelet count less than 100 x 10(9)/L, bulky adenopathy or organomegaly, symptomatic hyperviscosity,

72 All of these patients had bulky adenopathy or organomegaly.

73 Mediastinal adenopathy or pleural effusions were classified as typic

74 tases were often associated with mediastinal adenopathy or suspected extrapulmonary nonnodal metastas

75 and neck and stage IV disease (N2 or N3 neck adenopathy) or recurrent local-regional disease and who

76 ally-defined resection margins and no portal adenopathy; other factors included presence of < or = 4

77 NS) vs MYD88(L265P)CXCR4(WT) presented with adenopathy (P < .01), further delineating differences in

78 of posterior cervical, inguinal or axillary adenopathy, palatine petechiae, splenomegaly, or atypica

79 sis were hepatosplenomegaly, retroperitoneal adenopathy, periportal adenopathy, mesenteric adenopathy

80 fever, aphthous stomatitis, pharyngitis, and adenopathy (PFAPA) syndrome.

81 ondary or other findings (mediastinal edema, adenopathy, pleural effusion, or a sternal or lung abnor

82 diographs demonstrated mediastinal widening, adenopathy, pleural effusions, and air-space disease.

83 3.1 [95% CI, 1.6-5.9]), inguinal or axillary adenopathy (specificity range, 0.82-0.91; positive LR ra

84 gs of lymphoproliferative disorders, such as adenopathy, splenomegaly, thymic enlargement, and hepato

85 ases with the presence of posterior cervical adenopathy (summary specificity, 0.87; positive LR, 3.1

86 atopoiesis with progressive splenomegaly and adenopathy, surviving only slightly longer than TGF-beta

87 -responding lesions and to large mediastinal adenopathy that was present at diagnosis.

88 primary tumors and limited mediastinal/hilar adenopathy), the convenience of hypofractionated radioth

89 denopathy, periportal adenopathy, mesenteric adenopathy, thickening of the omentum and the mesentery,

90 This will allow reactive adenopathy to resolve and avoid unnecessary and costly a

91 l vaccination dose to allow for any reactive adenopathy to resolve.

92 Adenopathy (two patients) and vascular invasion (one pat

93 ancreatic ductal dilatation, local invasion, adenopathy, vascular invasion, vascular encasement, meta

94 g patients with unresectable (N3) NSCLC when adenopathy was not present on CT imaging and appears to

95 believed that the parotid mass and cervical adenopathy were technically resectable but that resectio

96 gocytosis, histologic profile, age, sex, and adenopathy) were significantly associated with survival.

97 All patients had multifocal adenopathy, which was massive in some patients; 14 of 15

98 omography images showed enlarged mediastinal adenopathy with increased [(18)F]fluorodeoxyglucose upta

99 Short-term follow-up of unilateral axillary adenopathy with recent COVID-19 vaccination is an approp

100 ion as LABC with ipsilateral supraclavicular adenopathy without evidence of distant disease, received

101 The adenopathy worsened despite withdrawal of immunosuppress